MYC and cancer: Recent data have shown how ATF4, MYC and mTORC1 stress-response pathways may converge in cancers that are reliant on glutamine [41–45], such as triple-negative breast cancer, where oncogenic MYC is a suspected driver of glutamine-reliance [46].